Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Recipient : Sirion Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration combines SIRION’s adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy and expertise in viral vector development and production with CRG’s deep knowledge of genetic regulatory mechanisms.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 16, 2022
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : Sirion Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?